Beta Bionics, Inc
NASDAQ: BBNXIrvine, US · Founded 2015 · Delaware corporation · 1 known investors
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription. The company operates in the medical device and diabetes care space.
Founders & leadership
Beta Bionics, Inc was founded in 2015 by Edward Damiano.
ED
Edward DamianoFounder
GC
Gilbert ClarkeNamed on SEC filing
ER
Edward RaskinNamed on SEC filing
MR
Mike RoskinoNamed on SEC filing
AM
Agustin MohedasNamed on SEC filing
JH
Jeff HitchcockNamed on SEC filing
SR
Serafina RaskinNamed on SEC filing
AS
Adam SteensbergNamed on SEC filing
Investors · 1
Funding
SEC filings, press & company announcements$277.5M disclosed across 4 of 5 rounds · 2017–2025
- Undisclosed amountinitial public offeringJan 2025Source ↗
▶$99.5MraisedSep 2023 · 29 investors · Other Health CareRule 506(b)
▶$99.5MraisedSep 2023 · 29 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Sean D. CarneyDirector
- Stephen H. FeiderExecutive Officer
- Lennox KetnerDirector
- Francesco DraettaDirector
- Amanda BlackDirector
- Edward DamianoExecutive Officer, Director
- Sean T. SaintExecutive Officer, Director
- Gilad GlickDirector
- Westley DuprayDirector
- Parker CassidyDirector
- Offering amount
- $101.8M
- Amount sold
- $99.5M
- First sale
- Aug 2023
- Incorporated
- Corporation, Massachusetts
- Federal exemptions
- 06b
▶$57MraisedMar 2022 · 21 investors · Other Health CareRule 506(b)
▶$57MraisedMar 2022 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward DamianoDirector
- Gibb ClarkeExecutive Officer
- Sean CarneyDirector
- Marcie CainExecutive Officer
- Finny KuruvillaDirector
- Beth BrookeDirector
- Michael PereiraExecutive Officer
- Veena RaoExecutive Officer
- Martha AronsonExecutive Officer, Director
- Jeff HitchcockDirector
- Christy JonesDirector
- Offering amount
- $57M
- Amount sold
- $57M
- First sale
- Feb 2022
- Incorporated
- Corporation, Massachusetts
- Federal exemptions
- 06b
▶$63.4MraisedJul 2019 · 12 investors · Other Health CareRule 506(b)
▶$63.4MraisedJul 2019 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward DamianoExecutive Officer, Director
- Gilbert ClarkeExecutive Officer
- Edward RaskinExecutive Officer, Director
- Mike RoskinoExecutive Officer
- Agustin MohedasDirector
- Jeff HitchcockDirector
- Serafina RaskinExecutive Officer
- Adam SteensbergDirector
- Offering amount
- $63.4M
- Amount sold
- $63.4M
- First sale
- Jul 2019
- Incorporated
- Corporation, Massachusetts, 2015
- Federal exemptions
- 06b
▶$57.6MraisedOct 2018 · 24 investors · Other Health CareRule 506(b)
▶$57.6MraisedOct 2018 · 24 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey HitchcockDirector
- Deirdre IbsenDirector
- CHRISTIAN FogedDirector
- Edward B. RaskinExecutive Officer, Director
- THOMAS A. FITZGERALDExecutive Officer
- Serafina RaskinExecutive Officer
- Edward R. DamianoExecutive Officer, Director
- Mike RosinkoExecutive Officer
- Martin H LangeDirector
- Gilbert ClarkeExecutive Officer
- Amount sold
- $57.6M
- Minimum investment
- $1
- Sales commissions
- $825K
- Placement agents
- Piper Jaffray & Co.
- First sale
- Dec 2017
- Incorporated
- Corporation, Massachusetts, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Diabetes78 shared keywordsThe American Diabetes Association is a nonprofit organization focused on diabetes prevention, research, advocacy, and education, providing resources, community programs, and support for people living with diabetes and prediabetes in the United States. It also advocates for policy such as affordable insulin and hosts scientific and technology conferences.
DexCom52 shared keywordsDexcom develops continuous glucose monitoring (CGM) systems and glucose biosensors, including the Dexcom G7 and the over-the-counter Stelo biosensor, that send real-time glucose readings to a phone or receiver. Its products serve people managing diabetes as well as consumers tracking glucose for general health, diet, and exercise.
Companies competing with Beta Bionics, Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase IISTTR | 2020 | $779.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.6M |
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase ISTTR | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $425K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Beta Bionics, Inc do?
- Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription. The company operates in the medical device and diabetes care space.
- Who founded Beta Bionics, Inc?
- Beta Bionics, Inc was founded by Edward Damiano in 2015.
- Who are Beta Bionics, Inc's investors?
- Beta Bionics, Inc's investors include Omega Funds.
- How much funding has Beta Bionics, Inc raised?
- Beta Bionics, Inc has disclosed $277.5M raised across 4 of its 5 known rounds.
- Where is Beta Bionics, Inc headquartered?
- Beta Bionics, Inc is headquartered in Irvine, US.